

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Leishmaniasis	CD40; IL-10; IL-12	<i>In vitro</i> and mouse studies suggest that boosting membrane cholesterol concentrations in macrophages could help treat <i>Leishmania major</i> infection. In mice infected with <i>L. major</i> , the cholesterol synthase inhibitor lovastatin promoted leishmaniasis, whereas mevalonate, which increases membrane cholesterol, had the opposite effect. Clinical studies are underway to test the therapeutic strategy.	Findings unpatented; unavailable for licensing	Rub, A. <i>et al. Nat. Immunol.</i> ; published online Feb. 8, 2009; doi:10.1038/ni.1705 <b>Contact:</b> Bhaskar Saha, National Centre for Cell Science, Ganeshkhind, Pune, India e-mail: <a href="mailto:sahab@nccs.res.in">sahab@nccs.res.in</a>
		<b>SciBX 2(7); doi:10.1038/scibx.2009.282</b> Published online Feb. 19, 2009		